Inuνair Nexthaler (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

Formoterol fumarate dihydrate is a long‑acting β2‑adrenergic agonist. It binds to β2 receptors on airway smooth muscle, activating adenylate cyclase, increasing cyclic AMP, and causing sustained relaxation of the bronchial muscles. This results in prolonged bronchodilation, helping keep the airways open for symptom control.

The exact dosing regimen for Inuνair Nexthaler is determined by the prescribing healthcare professional based on the patient’s disease severity, age, and response to therapy. Typically, the inhaler is used twice daily, but the prescriber will provide specific instructions tailored to each individual.

Safety data for Inuνair Nexthaler in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their physician.

To request Inuνair Nexthaler, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Inuνair Nexthaler offers a comparable efficacy profile to other LABA/ICS combinations, delivering both bronchodilation and anti‑inflammatory effects. Its Nexthaler dry‑powder device provides consistent dose delivery and may be preferred by patients who find breath‑actuated inhalers easier to use than metered‑dose sprays.

Store the inhaler at ambient temperature below 25 °C, protected from moisture and direct sunlight. Keep it in the original packaging until use, and avoid exposing it to extreme heat or humidity, which could affect dose consistency and device performance.

Inuνair Nexthaler is a dry‑powder inhaler. The patient should open the device, exhale fully away from the inhaler, place the mouthpiece in the mouth, and inhale quickly and deeply through the device. After inhalation, hold the breath for about 5–10 seconds before exhaling.

Serious risks include paradoxical bronchospasm, severe allergic reactions such as anaphylaxis, adrenal suppression with long‑term use, and an increased incidence of pneumonia in COPD patients. Patients should seek immediate medical attention if they experience sudden worsening of breathing or signs of an allergic reaction.

Inuνair Nexthaler should be avoided in individuals with known hypersensitivity to formoterol, beclometasone, or any excipients in the inhaler. Caution is advised for patients with certain cardiovascular disorders, uncontrolled hypertension, or a history of severe allergic reactions. Use in children is only appropriate if the product is approved for that age group.